The Laos Daxiong version of Axitinib strictly adheres to international generic drug production standards, providing clinicians and patients with a validated treatment option while ensuring the same active ingredient as the original drug.
What are the purchase channels for the Laos Daxiong version of Axitinib?
The Laos Daxiong version of Axitinib is available in the specification of 5mg*30 tablets/box. For specific purchasing methods, it is recommended that you add professional customer service for detailed consultation.
Important safety considerations for Axitinib
The following safety issues require close attention during the use of Axitinib: First, hypertension. Some patients may develop hypertension or even hypertensive crisis. Blood pressure should be controlled before treatment, and regular monitoring and use of antihypertensive drugs if necessary are required during treatment. Second, arterial and venous thrombotic events (such as myocardial infarction, stroke, pulmonary embolism) may occur, and patients with risk factors for thrombosis should use with caution. Third, hemorrhagic events (including fatal bleeding) have been reported, especially not suitable for patients with active gastrointestinal bleeding or untreated brain metastases. In addition, gastrointestinal perforation and fistula have also occurred, and at-risk patients should use cautiously. Hypothyroidism is relatively common, and thyroid function should be monitored regularly before and after treatment. Axitinib should be discontinued at least 24 hours before planned surgery. If signs of reversible posterior leukoencephalopathy syndrome (RPLS) (such as headache, seizures, visual disturbances) occur, treatment should be permanently discontinued. During treatment, regular monitoring of proteinuria, liver function (ALT, AST, bilirubin) is also required. Patients with moderate hepatic impairment require dose reduction, while severe hepatic impairment has not been studied. Women of childbearing potential should avoid pregnancy during treatment.
Common adverse reactions of Axitinib
In clinical studies, the most common adverse reactions (incidence ≥20%) of Axitinib include: diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), weight loss, vomiting, asthenia, and constipation. Among these, hypertension and hand-foot syndrome are more characteristic adverse reactions that require active management. Most adverse reactions are mild to moderate and can be managed by dose adjustment, symptomatic supportive care, or drug interruption. For example, diarrhea can be treated with antidiarrheal drugs and fluid replacement; hand-foot syndrome can be alleviated by moisturizing, avoiding high temperatures and pressure; hypertension requires the use of antihypertensive drugs such as ACEIs or CCBs. Patients should have regular follow-up during treatment and promptly report new or worsening symptoms to their doctor for early intervention. Serious adverse reactions (such as bleeding, thrombosis, hypertensive crisis, RPLS, etc.) have a low incidence but require vigilance and immediate medical attention.
